Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Julphar
Cerilliant
Fuji
Citi
McKesson
Chubb
Harvard Business School

Generated: November 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GALANTAMINE HYDROBROMIDE

« Back to Dashboard

Clinical Trials for Galantamine Hydrobromide

Trial ID Title Status Sponsor Phase Summary
NCT00077727 A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive impairment in patients with schizophrenia.
NCT00216593 Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study Completed Janssen Pharmaceutica N.V., Belgium Phase 3 The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
NCT00236431 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
NCT00236574 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
NCT00297362 A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease Completed Janssen Cilag Pharmaceutica S.A.C.I., Greece Phase 4 The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to galantamine hydrobromide.
NCT00338117 Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease Completed Shire Phase 3 The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
NCT00338117 Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Galantamine Hydrobromide

Condition Name

Condition Name for Galantamine Hydrobromide
Intervention Trials
Dementia 4
Alzheimer Disease 4
Alzheimer's Disease 2
Schizophrenia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Galantamine Hydrobromide
Intervention Trials
Alzheimer Disease 6
Dementia 4
Cognition Disorders 4
Mild Cognitive Impairment 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Galantamine Hydrobromide

Trials by Country

Trials by Country for Galantamine Hydrobromide
Location Trials
United States 3
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Galantamine Hydrobromide
Location Trials
Tennessee 1
Connecticut 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Galantamine Hydrobromide

Clinical Trial Phase

Clinical Trial Phase for Galantamine Hydrobromide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Galantamine Hydrobromide
Clinical Trial Phase Trials
Completed 11
Terminated 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Galantamine Hydrobromide

Sponsor Name

Sponsor Name for Galantamine Hydrobromide
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4
Dr. Reddy's Laboratories Limited 2
Actavis Inc. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Galantamine Hydrobromide
Sponsor Trials
Industry 12
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Baxter
Chinese Patent Office
Moodys
Mallinckrodt
McKinsey
Cantor Fitzgerald
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.